Hypothalamic Pharmacology · Module 4 of 4

Pituitary Adenoma Pharmacotherapy

Prolactinoma, Cushing disease, and acromegaly adjunct pharmacology

Cabergoline's advantages over bromocriptine are mechanistic, not incidental — higher D2R affinity and selectivity, a 63–68 hour half-life enabling twice-weekly dosing, and superior prolactin normalization rates (85–95% microadenomas, 70–85% macroprolactinomas) versus bromocriptine's shorter half-life and substantially higher rates of nausea, orthostasis, and other adverse effects; bromocriptine retains two specific advantages: the longest pregnancy safety record (>40 years) and substantially lower cost, making it the preferred agent when fertility is the immediate goal or in resource-limited settings.
The hook effect is an assay problem, not a clinical one — very high prolactin concentrations (from giant macroprolactinomas) saturate both capture and detection antibodies in immunometric assays, producing a falsely normal or low result; a large pituitary mass with an unexpectedly normal prolactin must always prompt 1:100 serum dilution before diagnosing a non-functioning adenoma, because misclassification leads to surgery for a tumor that would respond to a dopamine agonist.
Mifepristone monitoring uses clinical endpoints exclusively — cortisol and urinary free cortisol rise as an expected pharmacodynamic consequence of GR blockade (negative feedback is abolished) and cannot be used to assess efficacy or diagnose adrenal insufficiency; adrenal insufficiency on mifepristone is diagnosed clinically (hypotension, fatigue, hyponatremia) and treated empirically with high-dose hydrocortisone; mifepristone must also be discontinued to restore the feedback axis.
Steroidogenesis inhibitors have distinct drug interaction profiles that must not be confused — ketoconazole is a strong CYP3A4 inhibitor (dramatically raises cyclosporine, tacrolimus, statins) and requires LFTs every 2–4 weeks; mitotane is a potent CYP3A4 and CYP2B6 inducer requiring warfarin dose increases of ≥50% and doubled or tripled glucocorticoid replacement doses; osilodrostat is a moderate CYP2D6 inhibitor (raises tricyclics and some beta-blockers) and also inhibits aldosterone synthase, causing hypokalemia and hypotension that metyrapone does not.
Nelson syndrome is bilateral adrenalectomy's predictable consequence in Cushing disease — permanent loss of cortisol negative feedback drives unchecked ACTH hypersecretion from the residual corticotroph tumor, producing rapid tumor enlargement, visual field loss, cavernous sinus invasion, and striking hyperpigmentation; prevention by pituitary radiotherapy after adrenalectomy reduces but does not eliminate the risk; management once established includes repeat surgery, stereotactic radiosurgery, and temozolomide for aggressive tumors.

Abbreviations: D2R = dopamine type 2 receptor · ACTH = adrenocorticotropic hormone · UFC = urinary free cortisol · GR = glucocorticoid receptor · SSTR = somatostatin receptor subtype · CYP = cytochrome P450 · GLP-1 = glucagon-like peptide-1 · LFT = liver function test · INR = international normalized ratio · MRI = magnetic resonance imaging · MSH = melanocyte-stimulating hormone · 5-HT2B = serotonin 5-hydroxytryptamine 2B receptor · hERG = human ether-à-go-go-related gene

Prolactinoma — Dopamine Agonists Compared

Cabergoline — First-Line

High D2R Selectivity, Twice-Weekly Dosing

t½ 63–68 h; start 0.25 mg twice weekly → titrate q4 weeks; usual effective dose 0.5–2 mg/week
Prolactin normalization: 85–95% microadenomas; 70–85% macroprolactinomas
Tumor volume reduction in 80–90%; normalization of tumor size possible with prolonged treatment
Cardiac valvulopathy (5-HT2B on valve fibroblasts): echocardiogram at baseline; periodically if >2 mg/week
CYP3A4 substrate; dopamine antagonists (antipsychotics, metoclopramide) oppose effect
Withdrawal after ≥2 years normalized prolactin + no tumor on MRI: ~65–70% remain normoprolactinemic at 1 year

Bromocriptine — Alternative

Shorter Acting, Better Pregnancy Safety Record

t½ 6–8 h; twice or three times daily oral dosing
Higher nausea, vomiting, orthostatic hypotension than cabergoline
Longest pregnancy safety record (>40 years) — preferred when fertility is the immediate goal
Substantially less expensive — preferred in resource-limited settings
Dopamine agonist resistance: ~10–15% of prolactinoma patients; more common with large invasive tumors (reduced D2R expression)
Rare: pleuropulmonary fibrosis and retroperitoneal fibrosis with long-term high-dose use

Cushing Disease — Pharmacotherapy by Level of Action

Drug	Level of Action	Mechanism	Key Toxicity / Interaction	Monitor
Pasireotide	Pituitary (ACTH)	Pan-SSTR agonist → ↓ ACTH from corticotrophs (SSTR5 > SSTR2)	Hyperglycemia >70% (cortisol-driven metabolic risk + SSTR5 insulin suppression); prefer GLP-1 agonist or insulin	UFC q4–6 weeks; HbA1c; glucose
Cabergoline	Pituitary (ACTH)	D2R agonist → ↓ ACTH; UFC normalization ~25–40%	Resistance in 12–24 months; cardiac valvulopathy more relevant at Cushing doses (1–7 mg/week)	UFC; echocardiogram if >2 mg/week
Ketoconazole	Adrenal (steroidogenesis)	Inhibits CYP11A1, CYP11B1, CYP17A1 → ↓ cortisol at multiple steps	Hepatotoxicity (LFTs q2–4 weeks); strong CYP3A4 inhibitor (cyclosporine, tacrolimus, statins); QTc prolongation (hERG inhibition)	UFC; LFTs; ECG; avoid QT drugs
Metyrapone	Adrenal (steroidogenesis)	Selective CYP11B1 inhibitor → 11-deoxycortisol accumulates	Mineralocorticoid precursor accumulation → hypokalemia, hypertension; hirsutism/acne; nausea; limited CYP interactions	UFC; BP; K⁺; 11-deoxycortisol
Osilodrostat	Adrenal (steroidogenesis)	CYP11B1 + CYP11B2 inhibitor → ↓ cortisol and ↓ aldosterone	Hypotension and hypokalemia (aldosterone deficiency); QTc prolongation; moderate CYP2D6 inhibitor (tricyclics, beta-blockers)	UFC; electrolytes; BP; ECG
Mitotane	Adrenal (cytotoxic)	Adrenocortical cell destruction + multi-enzyme inhibition; take with fatty food	Potent CYP3A4 and CYP2B6 inducer: warfarin (↑dose ≥50%); glucocorticoids (double or triple replacement); OCP efficacy impaired; neurotoxicity (ataxia, confusion)	Plasma level 14–20 mg/L; INR q2 weeks; lifelong steroid replacement
Mifepristone	Target tissue (GR block)	GR antagonist → blocks cortisol action; cortisol and ACTH RISE (expected, not failure)	Cortisol NOT useful for monitoring; endometrial thickening in women; strong CYP3A4 inhibitor; PR antagonist → vaginal bleeding	Clinical endpoints ONLY: glucose, BP, weight; annual endometrial ultrasound in women

High-Yield Clinical Pearls

Hook Effect — Assay Artifact

Large Tumor, Falsely Normal Prolactin

Extremely high prolactin saturates both capture and detection antibodies in immunometric assay → no signal
Result: falsely normal or low prolactin on standard assay despite giant macroprolactinoma
Risk: mass misclassified as non-functioning adenoma → surgery when dopamine agonist would suffice
Fix: request 1:100 serum dilution — true prolactin unmasks and confirms dopaminergic therapy, not surgery
Rule: always dilute when a large pituitary mass has an unexpectedly normal or low prolactin

Nelson Syndrome — Post-Adrenalectomy ACTH Excess

Loss of Cortisol Feedback → Rapid Tumor Growth

Develops after bilateral adrenalectomy for refractory Cushing disease
Cortisol negative feedback permanently lost → unchecked ACTH hypersecretion (often >500 pg/mL)
Corticotroph tumor enlarges rapidly: visual field loss, cavernous sinus invasion
Hyperpigmentation: ACTH-driven MSH activity on melanocytes
Prevention: pituitary radiotherapy after bilateral adrenalectomy reduces (but does not eliminate) risk
Treatment: repeat surgery, stereotactic radiosurgery, temozolomide (aggressive tumors), pasireotide, cabergoline

Chapter Complete — Hypothalamic Pharmacology (HYPO) · Key Clinical Rules

Mifepristone monitoring uses clinical endpoints only — never cortisol or urinary free cortisol. GR blockade abolishes negative feedback, so cortisol and ACTH rise as an expected pharmacodynamic response. Rising cortisol on mifepristone is not treatment failure. Adrenal insufficiency on mifepristone is diagnosed clinically (hypotension, fatigue, hyponatremia) and managed with empirical high-dose hydrocortisone; discontinue mifepristone to restore the feedback axis.

The hook effect is a dilution problem. Any large pituitary mass with a normal or unexpectedly low prolactin requires 1:100 serum dilution before the adenoma is classified as non-functioning. Misclassification leads to unnecessary surgery for a tumor that would respond to cabergoline.

Steroidogenesis inhibitor drug interactions are drug-specific and clinically consequential. Ketoconazole is a strong CYP3A4 inhibitor — avoid or dramatically reduce cyclosporine, tacrolimus, and statin doses. Mitotane is a potent CYP3A4 and CYP2B6 inducer — warfarin doses must increase ≥50%; glucocorticoid replacement doses must double or triple. Osilodrostat is a moderate CYP2D6 inhibitor affecting tricyclics and certain beta-blockers. All steroidogenesis inhibitors share adrenal insufficiency risk — every patient needs a stress-dose hydrocortisone prescription and an injectable hydrocortisone kit.

Nelson syndrome prevention should be planned at the time of bilateral adrenalectomy. Pituitary radiotherapy before or immediately after bilateral adrenalectomy reduces the risk of rapid corticotroph tumor expansion. Once Nelson syndrome develops, extremely high ACTH (>500 pg/mL) with hyperpigmentation and mass effect signals an aggressive tumor that may require temozolomide in addition to surgery and radiotherapy.

GnRH pulsatility determines pharmacodynamic direction — the same receptor, the same agonist, opposite outcomes depending on delivery pattern. Depot GnRH agonists suppress gonadotropins through receptor downregulation; pulsatile GnRH pump therapy stimulates them. Antagonists (degarelix, relugolix) bypass the flare entirely and achieve faster testosterone recovery after discontinuation, with relugolix showing a 54% lower MACE rate versus leuprolide in the HERO trial.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 40: Estrogens, Progestins, and the Female Reproductive Tract	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 44: Estrogens and Progestins	McGraw-Hill; 2023
Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society.	Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline	J Clin Endocrinol Metab. 2011;96(2):273–288
Casanueva FF, Molitch ME, Schlechte JA, et al.	Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas	Clin Endocrinol (Oxf). 2006;65(2):265–273
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF.	A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea	N Engl J Med. 1994;331(14):904–909
Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G.	Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia	N Engl J Med. 2003;349(21):2023–2033
Molitch ME.	Pharmacologic resistance in prolactinoma patients	Pituitary. 2005;8(1):43–52
Abs R, Verhelst J, Maiter D, et al.	Cabergoline in the treatment of acromegaly: a study in 64 patients	J Clin Endocrinol Metab. 1998;83(2):374–378
Gadelha MR, Bronstein MD, Brue T, et al; PAOLA study investigators.	Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial	Lancet Diabetes Endocrinol. 2014;2(11):875–884
Nieman LK, Biller BMK, Findling JW, et al; Endocrine Society.	Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline	J Clin Endocrinol Metab. 2015;100(8):2807–2831
Colao A, Petersenn S, Newell-Price J, et al; Pasireotide B2305 Study Group.	A 12-month phase 3 study of pasireotide in Cushing's disease	N Engl J Med. 2012;366(10):914–924
Pivonello R, De Martino MC, Cappabianca P, et al.	The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery	J Clin Endocrinol Metab. 2009;94(1):223–230
Castinetti F, Guignat L, Giraud P, et al.	Ketoconazole in Cushing's disease: is it worth a try?	J Clin Endocrinol Metab. 2014;99(5):1623–1630
Fleseriu M, Pivonello R, Young J, et al.	Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease	Pituitary. 2016;19(2):138–148
Terzolo M, Angeli A, Fassnacht M, et al.	Adjuvant mitotane treatment for adrenocortical carcinoma	N Engl J Med. 2007;356(23):2372–2380
Fleseriu M, Biller BMK, Findling JW, Molitch ME, Schteingart DE, Gross C; SEISMIC Study Investigators.	Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome	J Clin Endocrinol Metab. 2012;97(6):2039–2049
Barber TM, Adams E, Ansorge O, Byrne JV, Karavitaki N, Wass JA.	Nelson's syndrome	Eur J Endocrinol. 2010;163(4):495–507